Archive: September 01 2020
Find relevant news articles from other European projects, below:
CARAMBA EURE-CART CARAT Network ATECT PROCROP
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Fundamentals of nanoparticles in cancer immunotherapy and radiotherapy
Dr Selvaraj describes the future developments in this area, where next-generation nanoparticles could be developed to enhance the active targeting of tumour cells, and the compatibility with other anti-cancer therapies.
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
Immune checkpoint inhibitors (ICIs) commonly target CTLA-4, PD-1, and PD-L1, which promote inhibitory signals on immune effector T cells against cancer cells. Although ICIs have improved outcomes in several cancers, their use is also associated with significant adverse events (AEs), including death.
CAR T-Cell Optimization Starts in Production, Extends to Therapy
New technologies allow finer control of CAR T cells at every level—manufacturing, assessments of tissue penetrance, targeting, potency, and dosing.